date,title,source
Nov-01-18,Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients,PR Newswire
Nov-07-18,Sierra Oncology to Present at the Jefferies 2018 London Healthcare Conference,CNW Group
Nov-08-18,Sierra Oncology Reports Third Quarter Results,CNW Group
Nov-13-18,Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium,CNW Group
Nov-15-18,Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium,PR Newswire
Nov-27-18,Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit,CNW Group
Nov-29-18,Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737,CNW Group
Dec-03-18,Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib,CNW Group
Jan-22-19,"Do Institutions Own Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?",Simply Wall St.
Jan-23-19,Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit,CNW Group
Feb-27-19,Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data,CNW Group
Feb-28-19,Sierra Oncology Reports 2018 Year End Results,CNW Group
Mar-05-19,Sierra Oncology to Present at the Cowen 39th Annual Health Care Conference in Boston,CNW Group
Apr-01-19,Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019,PR Newswire
Apr-01-19,Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019,CNW Group
Apr-03-19,Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019,CNW Group
